Ledipasvir and sofosbuvir combination for hepatitis C virus infection in three patients aged 85 years and older. - Suppr | 超能文献

Ledipasvir and sofosbuvir combination for hepatitis C virus infection in three patients aged 85 years and older.

作者信息

Ji Fanpu, Tian Changyin, Li Zongfang, Deng Hong, Nguyen Mindie H

机构信息

aDepartment of Infectious Diseases bShaanxi Provincial Clinical Research Center for Hepatic and Splenic Diseases cNational and Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China dDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA.

出版信息

Eur J Gastroenterol Hepatol. 2017 Aug;29(8):977-979. doi: 10.1097/MEG.0000000000000873.

DOI:10.1097/MEG.0000000000000873

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Ledipasvir and sofosbuvir combination for hepatitis C virus infection in three patients aged 85 years and older.

Eur J Gastroenterol Hepatol. 2017 Aug;29(8):977-979. doi: 10.1097/MEG.0000000000000873.

2

Ledipasvir + sofosbuvir (Harvoni). A therapeutic advance in genotype 1 hepatitis C virus infection, despite uncertainties.来迪派韦+索磷布韦（哈瓦尼）。尽管存在不确定性，但在1型丙型肝炎病毒感染的治疗上取得了进展。

Prescrire Int. 2015 Dec;24(166):285-9.

3

Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus.来迪派韦/索磷布韦固定剂量复方片剂用于台湾慢性基因1型丙型肝炎病毒患者。

J Gastroenterol Hepatol. 2016 Jul;31(7):1323-9. doi: 10.1111/jgh.13305.

4

The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection.来迪派韦索磷布韦治疗 12-17 岁 1 型丙型肝炎病毒感染青少年的安全性和有效性。

Hepatology. 2017 Aug;66(2):371-378. doi: 10.1002/hep.28995. Epub 2017 Jun 19.

5

Membranous nephropathy associated with hepatitis C virus infection treated with corticosteroids and Ledipasvir-Sofosbuvir: a case report and review of literature.应用皮质类固醇和来迪派韦-索磷布韦治疗丙型肝炎病毒感染相关的膜性肾病：一例报告并文献复习

Oncotarget. 2017 Mar 28;8(13):22299-22303. doi: 10.18632/oncotarget.15397.

6

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.来迪派韦索磷布韦片与索磷布韦联用治疗初治的 HCV 基因 1 型感染。

N Engl J Med. 2014 May 15;370(20):1889-98. doi: 10.1056/NEJMoa1402454. Epub 2014 Apr 11.

7

Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.来迪派韦-索磷布韦：用于慢性丙型肝炎病毒感染的无干扰素/利巴韦林治疗方案。

Ann Pharmacother. 2015 Mar;49(3):343-50. doi: 10.1177/1060028014563952. Epub 2014 Dec 16.

8

Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.索磷布韦维帕他韦治疗 5 型丙型肝炎病毒感染患者：一项开放标签、多中心、单臂、2 期研究。

Lancet Infect Dis. 2016 Apr;16(4):459-64. doi: 10.1016/S1473-3099(15)00529-0. Epub 2016 Jan 21.

9

Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection.利巴韦林联合索磷布韦治疗 8 周或 12 周对 HCV 基因 2 型感染患者的疗效。

Gastroenterology. 2017 May;152(6):1366-1371. doi: 10.1053/j.gastro.2017.01.017. Epub 2017 Jan 27.

10

Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.利巴韦林联合或不联合 ledipasvir 和 sofosbuvir 治疗 12 周治疗 HCV 基因型 3 或 6 感染患者的疗效。

Gastroenterology. 2015 Nov;149(6):1454-1461.e1. doi: 10.1053/j.gastro.2015.07.063. Epub 2015 Aug 7.

引用本文的文献

1

Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients.评估 HCV 感染患者接受基于索非布韦方案治疗前后的整体纵向应变对心功能的影响。

BMC Infect Dis. 2018 Oct 16;18(1):518. doi: 10.1186/s12879-018-3426-9.

2

Efficacy and safety of sofosbuvir and ledipasvir in Japanese patients aged 75 years or over with hepatitis C genotype 1.索磷布韦和来迪派韦在75岁及以上日本丙型肝炎1型患者中的疗效与安全性。

World J Hepatol. 2017 Dec 28;9(36):1340-1345. doi: 10.4254/wjh.v9.i36.1340.